Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MorphoSys, Lanthio Pharma ink tech allianceMorphoSys, Lanthio Pharma ink tech alliance
January 2013
SHARING OPTIONS:

PLANEGG, GermanyŚMorphoSys AG and Dutch biopharmaceutical company Lanthio Pharma have established a collaboration to discover and develop lantipeptides, a novel class of therapeutics with high target selectivity and improved drug-like properties. LanthioPep, Lanthio Pharma's technology, can identify peptides that are selective for specific disease targets and stabilize them in the optimal structural formation for receptor binding. The companies will apply their respective technologies to establish lantipeptide-based libraries, and MorphoSys will receive preferred rights to exclusively license the LanthioPep technology for use in drug discovery. In addition, MorphoSys will make an equity investment in Lanthio Pharma in the latter's Series A financing round, and upon the transaction's close, will hold a minority stake in Lanthio Pharma. No financial details were disclosed.


 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.